A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs Zilebesiran (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms KARDIA-1
- Sponsors Alnylam Pharmaceuticals
- 27 Dec 2024 Status changed from active, no longer recruiting to completed.
- 30 Oct 2024 According to an Alnylam Pharmaceuticals media release, company will present a new analysis of the KARDIA-1 at the upcoming American Heart Association (AHA) Scientific Sessions 2024, November 16-18, 2024.
- 01 Jul 2024 Planned End Date changed from 4 Dec 2024 to 5 Dec 2024.